Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Portfolio Pulse from
VolitionRx Limited has announced its first commercial sale of its High Throughput Synthetic Sepsis method, which measures NETs activation and inhibition in real time. This marks an expansion of their commercial offerings and they are in discussions with pharmaceutical companies.
February 06, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VolitionRx Limited has made its first commercial sale of a new method for studying NETosis, expanding its commercial offerings and engaging in discussions with pharmaceutical companies.
The first commercial sale of a new product often indicates potential revenue growth and market expansion. The ongoing discussions with pharmaceutical companies suggest future partnerships or sales, which could positively impact VNRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100